Clinical Trials for Mesothelioma Patients—A Study of Carboplatin, Bevacizumab and Pemetrexed for MPM Patients: Exclusion Criteria

Read about the exclusion criteria for a current clinical trial about the use of Carboplatin, Bevacizumab and Pemetrexed for MPM patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Exclusion Criteria:
Patients with hypercalceamia (corrected calcium of more than 11 mg/dl) will be excluded.
Patients with history of hemoptysis, hemetemesis, coagulopathy or thrombosis will be excluded.
Patients requiring anticoagulation for any reason will be excluded.
History of palliative radiation therapy within 2 weeks
Blood pressure of >160/100 mmHg, despite adequate anti-hypertensive use.
Currently ongoing unstable angina
New York Heart Association (NYHA) Grade II or greater congestive heart failure. (Please see Appendix III.)
History of stroke within 6 months
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to the day of initiation of treatment, anticipation of need for major surgical procedure during the course of the study
Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to the day of initiation of treatment.
Pregnant (positive pregnancy test) or lactating
Urine calculated creatinine clearance of less than 40ml/minute. (Please see Appendix VI).
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
Serious, non-healing wound, ulcer, or bone fracture
Inability to comply with study and/or follow-up procedures

If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.